Calcium/Calmodulin-dependent Protein Kinase Kinase 2: Roles in Signaling and Pathophysiology*

Luigi Racioppi1,§ and Anthony R. Means1,‡¶2

From the Departments of *Pharmacology and Cancer Biology and *Medicine, Duke University Medical Center, Duke University, Durham, North Carolina 27710 and the †Department of Cellular and Molecular Biology and Pathology, University of Naples Federico II, 80131 Naples, Italy

Many cellular Ca2+-dependent signaling cascades utilize calmodulin (CaM) as the intracellular Ca2+-receptor. Ca2+/CaM binds and activates a plethora of enzymes, including CaM kinases (CaMKs). CaMKK2 is one of the most versatile of the CaMKs, and will phosphorylate and activate CaMKI, CaMKIV, and AMP-activated protein kinase. Cell expression of CaMKK2 is limited, yet CaMKK2 is involved in regulating many important physiological and pathophysiological processes, including energy balance, adiposity, glucose homeostasis, hematopoiesis, inflammation, and cancer. Here, we explore known functions of CaMKK2 and discuss its potential as a target for therapeutic intervention.

Ca2+ is a pervasive second messenger that controls many cell functions by forming a complex with calmodulin (CaM)1, which serves as a ubiquitous intracellular Ca2+ receptor. Upon Ca2+ binding, CaM increases its affinity for a large number of CaM-binding proteins, including three multifunctional CaM kinases (CaMKI, CaMKII, and CaMKIV) (3). For full activation, CaMKII and CaMKIV require phosphorylation on an activation loop Thr by CaMKK2 (CaMKK1 or CaMKK2, respectively). The requirement of two CaMKs in the same signaling pathway led to the concept of a CaMK cascade (4). In addition to its role in these enzymatic cascades, CaMKK2 is also a physiologically relevant upstream activator of the AMP-activated protein kinase (AMPK) (5–7), and one role for this CaMKK2-AMPK complex is the regulation of energy balance by acting in the hypothalamus (8).

*This work was supported, in whole or in part, by National Institutes of Health Grants GM033976 and DK074701 (to A. R. M.) and SU19-AI067798-07 (to L. R.). This article is part of the Thematic Minireview Series on Calcium Function and Disease.
1 To whom correspondence may be addressed. E-mail: luigi.racioppi@duke.edu.
2 To whom correspondence may be addressed. E-mail: tony.means@duke.edu.
3 The abbreviations used are: CaM, calmodulin; CaMK, CaM kinase; CaMKK, CaMK kinase; AMPK, AMP-activated protein kinase; CREB, cAMP response-element binding protein; GCC, cerebellar granule cell; GCP, granule cell precursor; EGL, external granule layer; ARC, hypothalamic arcuate nucleus; NPY, neuropeptide Y; AgRP, Agouti-related protein; WAT, white adipose tissue; HSC, hematopoietic stem cell; AR, androgen receptor; IP3, inositol 1,4,5-triphosphate.

This is an Open Access article under the CC BY license.

CaMKK2: Structure and Function

CaMKK2 is a 66–68-kDa kinase in rat, mouse, and man (9–14). Analysis of CaMKK2 cDNA clones revealed a >90% species similarity in the amino acid coding region but with heterogeneity in the 3’-noncoding termini (12–14). Similar to other CaMK family members, CaMKK2 consists of unique N- and C-terminal domains and a central Ser/Thr-directed kinase domain that is followed by a regulatory domain composed of overlapping autoinhibitory and CaM-binding regions (15). The deduced amino acid sequences of cloned CaMKK2 cDNAs reveal 30–40% sequence identity of the kinase homology domain to other members of the CaMK family. However, CaMKK2 contains a unique 22-residue Pro/Arg/Gly-rich insert between the ATP-binding and protein substrate motifs (11).

The human CaMKK2 locus spans over 40 kb pairs, maps to chromosome 12q24.2, and is organized into 18 exons and 17 introns (16). Two major transcripts are generated by use of polyadenylation sites present in the last two exons. Additionally, CaMKK2 transcripts can be generated by alternative splicing of internal exons 14 and/or 16; this mechanism produces variants with different roles in neuronal differentiation (16, 17). PKA and CaMKIV have been reported to be involved in regulation of alternative splicing of the CaMKK2 transcript (17).

Analysis of the sequences of the promoter and 5’-untranslated region of the human CaMKK2 gene identified consensus DNA-binding sequences for several transcription factors, including Ikaros, RUNX1 (Runt-related transcription factor 1), and GATA1 (GATA-binding factor 1). The expression of these transcription factors is typically restricted to stem cell progenitors, in which their role is to regulate hematopoiesis and neurogenesis (19–21). This may be relevant to the fact that CaMKK2 is expressed in a restricted number of cell types, as well as the involvement of CaMKK2 in processes regulating development of neurons and blood progenitors (22, 23).

The most well-characterized substrates of CaMKK2 are CaMKI and CaMKIV. CaMKK2 phosphorylates CaMKIV and CaMKI on activation loop Thr residues (Thr-200 and Thr-177, respectively), which increases their kinase activities. Accordingly, mutation of the Thr residue abolishes both phosphorylation and activation of CaMKI/CaMKIV by CaMKK2 (12). More recently, AMPKα was shown to be an additional substrate of CaMKK2. Phosphorylation and activation of AMPK occur in response to an increase in intracellular Ca2+ in LKB1 (liver kinase B1)-deficient cells, and this effect is dependent on CaMKK2 (5). Down-regulation of CaMKK2 in mammalian cells using RNA interference almost completely abolishes AMPK activation (6). Finally, purified CaMKK2 will phosphorylate and activate AMPKα in vitro (6), and these two kinases form a stable multiprotein complex consisting of Ca2+ /CaM, CaMKK2, AMPKα, and AMPKβ (8), which is regulated by Ca2+, but not by AMP, due to the absence of the AMP-binding subunit. Green et al. (24) demonstrated that CaMKK2 and AMPK associate through their kinase domains and found that CaMKK2 must be in an active conformation to bind AMPK, but not to associate with other substrates, such as CaMKIV. These
findings suggest the hypothesis that signals modifying the activation status of CaMKK2 may act as molecular switches to couple CaMKK2 with AMPK- and/or CaMK-dependent pathways.

The molecular mechanism regulating the enzymatic activity of CaMKK2 is still not completely defined (Fig. 1). CaMKKs are autoinhibited by a sequence located immediately C-terminal to their catalytic domain. This includes overlapping autoinhibitory and CaM-binding regions that are similar to those found in CaMKI and CaMKIV (11). However, the x-ray structure of CaMKK bound to this region reveals that the structure of the bound CaMKK domain is markedly different from those of other CaMK CaM-binding domains whose structures have been solved (25). Clearly CaMKK binding causes unique conformational changes in the CaMKKs relative to other CaMKs, although the mechanistic reason for this difference remains to be clarified.

CaMKK2 exhibits significant activity even in the absence of CaMKK binding (autonomous activity) (12). By using truncation mutants of CaMKK2, a region of 23 amino acids (residues 129–151) located at the N terminus of the catalytic domain was identified as an important regulatory element. CDK5 and GSK3 phosphorylate Ser-129, Ser-133, and Ser-137. PKA phosphorlates Ser-100, Ser-495, and Ser-511. Thr-482 has been identified as an auto/transphosphorylation site. Although CaMKK2 has autonomous activity for some substrates, binding to CaMKK relieves autoinhibition, resulting in a fully active kinase. Mutation of Ser-129, Ser-133, and Ser-137 increases autonomous activity with little change in CaMKK-dependent activity. Of note, mutation of Ser-129, Ser-133, and Ser-137 also decreases the stability of CaMKK2. This implies that the autonomously active CaMKK2 generated by dephosphorylation of these Ser residues would display a shorter half-life and be more rapidly degraded. Mutation of PKA residues does not affect CaMKK autonomous activity. Phosphorylation of Ser and Thr residues is depicted as blue and red clouds, respectively.

**FIGURE 1. Schematic representation of the structure-activity relationships of CaMKK2.**

A, CaMKK2 consists of unique N- and C-terminal domains (blue and green, respectively) and a central Ser/Thr-directed kinase domain (red) that is followed by a regulatory domain composed of overlapping autoinhibitory and CaM-binding regions (Autoreg/CaM, gray). A region of 23 amino acids (residues 129–151) located at the N terminus of the catalytic domain has been identified as an important regulatory element. CDK5 and GSK3 phosphorylate Ser-129, Ser-133, and Ser-137. PKA phosphorlates Ser-100, Ser-495, and Ser-511. Thr-482 has been identified as an auto/transphosphorylation site. B, although CaMKK2 has autonomous activity for some substrates, binding to CaMKK relieves autoinhibition, resulting in a fully active kinase. Mutation of Ser-129, Ser-133, and Ser-137 increases autonomous activity with little change in CaMKK-dependent activity. Of note, mutation of Ser-129, Ser-133, and Ser-137 also decreases the stability of CaMKK2. This implies that the autonomously active CaMKK2 generated by dephosphorylation of these Ser residues would display a shorter half-life and be more rapidly degraded. Mutation of PKA residues does not affect CaMKK autonomous activity. Phosphorylation of Ser and Thr residues is depicted as blue and red clouds, respectively.
olfactory bulb, hippocampus, dentate gyrus, amygdala, hypothalamus, and cerebellum (Refs. 12 and 14; see the Gene Expression Nervous System Atlas (GENSAT) (30)). In addition to the nervous system, CaMKKK2 is present at lower levels in testis, spleen, and lung (12, 31). In other tissues, such as kidney, intestine, and heart, the evidence for expression remains less clear (12, 31, 32).

CaMKK2 can be clearly detected in isolated murine preadipocytes, embryonic fibroblasts, and isolated hepatocytes and in human umbilical cord vein endothelial cells (32–34). Most recently, the presence of CaMKK2 in immune cells was examined and found exclusively in cells of the myeloid lineage, including bone marrow-derived and freshly isolated peritoneal macrophages (35).

**CaMKK2 and Brain Functions**

Calcium controls many neuronal functions, such as neurotransmitter synthesis and secretion and dendritic spine morphology (36). Thus, it is not surprising that proteins involved in Ca$^{2+}$-dependent pathways, such as CaMKKK2, play critical roles in the development of neurons and brain physiology (37, 38).

**Hippocampal Memory**—Germ-line ablation of CaMKKK2 impairs long-term memory formation (39, 40). The absence of CaMKKK2 is associated with selective loss of long-term potentiation at hippocampal CA1 synapses and with a decrease in spatial training-induced cAMP response-element binding protein (CREB) activation in the hippocampus (39). However, in contrast to CaMKKK1$^{-/-}$ mice, loss of CaMKKK2 does not correlate with deficits in fear conditioning (41).

Initiation and maintenance of synaptic plasticity in CA1 pyramidal neurons of the hippocampus require morphological changes in dendritic spines, which constitute the main structural basis for memory formation (42). Studies in cultured neurons revealed requirements for a CaMKKK/CaMKK1 cascade in regulation of axonal growth cone morphology and outgrowth, dendritic arborization, and spine and synapse formation (37). CaMKK and CaMKK1 co-localize with βPIX (p21-activated kinase-interacting exchange factor) and GIT1 (G-protein-coupled receptor kinase-interacting protein 1) in dendritic spines as part of a multiprotein complex that regulates actin dynamics (43). Differential splicing and phosphorylation of critical Ser residues affect the ability of CaMKKK2 to control dendrite/axon formation (17, 27). Thus, a CaMKKK2/CaMKK1 cascade regulates learning-induced neuronal cytoskeleton remodeling associated with memory formation.

**Cerebellar Development**—Cerebellar granule cells (CGCs) are the most abundant neurons in the cerebellum. They develop from granule cell precursors (GCPs), which migrate from the rhombic lip to form a secondary proliferative zone in the external granule layer (EGL) (44, 45). During postnatal development, GCPs in the EGL cease proliferation and migrate again to form the internal granule layer, where they make synaptic connections with Purkinje cells. This complex process is fine-tuned by BDNF, which influences CGC development by promoting GCP exit from the cell cycle and acting as a chemokinetic factor to induce GCP migration. CaMKKK2 is expressed in the cerebellum, as well as in isolated CGCs (14, 46). Studies with mouse models revealed that loss of CaMKKK2 or its downstream target CaMKIV impairs the ability of GCPs to cease proliferation in the EGL and migrate to the internal granule layer (23). This phenotype is correlated with decreased CREB phosphorylation and reduced BDNF expression in GCPs. Thus, a CaMKKK2/CaMKIV/CREB signaling cascade is required for regulation of BDNF production in the postnatal cerebellum and execution of the program that mediates CGC development.

**Hypothalamus**—The hypothalamus serves as a center for integration of hormonal and nutrient signals to modulate food intake, energy expenditure, and peripheral glucose metabolism (47, 48). Multiple neuronal populations residing in the hypothalamic arcuate nucleus (ARC) play a critical role in these regulatory circuits (47, 49). Due to their electrical activity and release of the orexigenic neuropeptide Y (NPY), NPY/Agouti-related protein (AgRP) neurons positively regulate feeding behavior. In contrast, pro-opiomelanocortin neurons inhibit feeding by releasing the α-melanocyte-stimulating hormone. AgRP neurons inhibit pro-opiomelanocortin neurons and thus serve a modulatory function to reduce satiety and promote food intake.

Ghrelin is a hormone produced in the intestine that exerts a potent central orexigenic effect by acting on hypothalamic NPY/AgRP neurons via activation of the growth hormone secretagogue receptor to promote release of NPY (50, 51). Ghrelin exerts its effects by binding to this G$_{s}$-coupled growth hormone secretagogue receptor, leading to an increase in intracellular Ca$^{2+}$ that is required for transcriptional activation of the NPY gene, and AMPK has been identified as one relevant signaling component (52). Accordingly, genetic ablation of CaMKKK2 impairs hypothalamic AMPK activity and down-regulates NPY and AgRP gene expression in NPY neurons, thus protecting mice from diet-induced obesity, hyperglycemia, and insulin resistance (8). Interestingly, because CaMKKK2 forms a complex with AMPKα/β and Ca$^{2+}$/CaM, this has been proposed to function as the physiologically relevant signaling complex for mediating CaMKKK2-mediated central effects on energy homeostasis (8).

CaMKKK2 is present in the medial hypothalamus, especially in ventromedial nuclei (8, 14, 53, 54). In these neurons, cell-specific gene inactivation studies revealed that brain-derived serotonin uses a CaMK cascade involving CaMKKK2 and CaMKIV to phosphorylate CREB in response to signaling through the Htr2c serotonin receptor. Thus, CaMKKK2 regulates the expression of genes necessary for optimal sympathetic activity and, in turn, bone mass accrual, which is negatively correlated with sympathetic tone (54). Serotonin also acts via its Htr1a and Htr2b receptors in ARC neurons to favor appetite and decrease energy expenditure (55). However, to date, neither the nature of the molecular events elicited by serotonin nor the role of CaMKKK2 in ARC neurons has been explored.

**CaMKKK2 in Adipose Tissue and Liver**

Although CaMKKK2$^{-/-}$ mice are protected from diet-induced obesity, glucose intolerance, and insulin resistance (8), they have more adipose tissue than WT mice when fed regular chow. Moreover, pair feeding of WT mice to match food consumption of CaMKKK2 mice slows weight gain but fails to pro-
tect from diet-induced glucose intolerance (32). Taken together, these findings suggested that CaMKK2 may participate in circuits regulating the metabolic response to overnutrition in peripheral metabolic tissues. Indeed, this idea has been confirmed by recent studies revealing roles for this kinase in adipogenesis and hepatic glucose metabolism (32, 33).

Adipogenesis—White adipose tissue (WAT) is an organ whose major function is to regulate energy homeostasis (56). Adipocytes differentiate from mesenchymal stem cells in a complex process known as adipogenesis, which begins in late gestation and is largely regulated by nutrient availability. In the adult, there is a general consensus that the number of adipocytes cannot increase by >10% after puberty. Although CaMKK2 is barely detectable in adult mouse WAT or in isolated adipocytes, this kinase is expressed in preadipocytes (33). Indeed, genetic ablation of CaMKK2 led to an increase in WAT mass, which correlated with a decrease in the number of preadipocytes in this tissue. Interestingly, when exposed in vitro to adipogenic stimuli, primary CaMKK2−/− preadipocytes display a greater ability to differentiate into adipocytes than do WT cells. Moreover, during the differentiation process of WT adipocytes, the increase in molecular markers of the mature fat cell inversely correlates with the disappearance of CaMKK2. Interestingly, the silencing of AMPKα exerts effects comparable to genetic ablation of CAMKK2 by promoting terminal differentiation of preadipocytes. Finally, inhibition of the CaMKK2/AMPK signaling cascade in preadipocytes reduces Pref-1 (preadipocyte factor 1) and Sox9 (SRY-related HMG box) mRNA, resulting in accelerated adipogenesis. Thus, CaMKK2/AMPKα functions in the signaling network that regulates adipocyte development (33).

Hepatic Glucose Metabolism—Although initial reports (11, 12, 31) failed to identify CaMKK2 in liver, this kinase is present in isolated hepatocytes (32). In fact, acute reduction of hepatic CaMKK2 reduces blood glucose in mice fed either a regular or high-fat diet (32). Notably, acute deletion of CaMKK2 in primary hepatocytes prevents the up-regulation of key enzymes of the gluconeogenesis pathway, such as glucose-6-phosphate dehydrogenase and phosphoenolpyruvate carboxykinase, in response to noradrenaline, an agonist of Ca2+ signaling. Moreover, freshly isolated hepatocytes from CaMKK2−/− mice also exhibit an increased rate of de novo lipogenesis relative to that of WT cells. Quiescent and noradrenaline-exposed CaMKK2-null hepatocytes express less mRNA encoding the PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α) compared with WT hepatocytes, and this defect may be responsible for impaired glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression (32). The PGC-1α promoter can be activated by the CREB-CREB-binding protein-TORC2 complex in response to PKA signaling and repressed by HDAC5 (histone deacetylase 5), a putative target of CaMKs (57–59). In primary hepatocytes, loss of CaMKK2 prevents phosphorylation of HDAC5 on two residues that are critical for repression of genes (32). These data inspired the idea that a CaMK2/CaMKI signaling cascade may control HDAC5 phosphorylation and, in turn, relief of repression of genes whose protein products are required for gluconeogenesis (32).

CaMKK2 and Myeloid Cell Physiology

CaMKK2 substrates control important functions in hematopoietic and immune cells (29, 60, 61). CaMKIV regulates survival of activated dendritic cells and the amplitude of the antibody response induced by vaccines (62, 63). CaMKI has been implicated in TLR4 (Toll-like receptor 4) signaling, as well as in the inflammatory response induced by sepsis (64), and AMPK plays an important role in the inflammatory response (65). Together, these findings suggest that CaMKK2 could be involved in the control of blood cell formation and inflammatory response. Indeed, recent reports identified functions for CaMKK2 in granulopoiesis and macrophage activation (22, 35).

Granulopoiesis—The formation of blood cells is a complex process in which hematopoietic stem cells (HSCs) self-renew or differentiate into more lineage-committed progenitors to ultimately generate all mature blood cells (66). The ability of HSCs to undergo self-renewal is partly regulated by external signals originating from the stem cell niche, and a high concentration of Ca2+ at the HSC-enriched endosteal surface provides a unique microenvironment for stem cells (67, 68). An implication of these data is that Ca2+/CaM-dependent pathways may play critical roles in hematopoiesis. Supporting this idea, CaMKIV is involved in regulating HSC survival and maintenance (61).

Most recently, CaMKK2−/− mice were found to possess reduced numbers of HSCs and total bone marrow cells (22). However, unlike the case for loss of CaMKIV, depletion of CaMKK2 did not affect the proliferation, survival, or function of HSCs. Rather, loss of CaMKK2 resulted in marked defects in early myeloid progenitor populations. Surprisingly, engraftment of CaMKK2-null HSCs by bone marrow transplant led to an increased repopulation of myeloid cells, and an increased ability of CaMKK2-null myeloid progenitors to differentiate into colony-forming unit-granulocytes and Gr1+Mac1− granulocytes was confirmed in vitro. Intriguingly, similar to adipocytes, expression of CaMKK2 inversely correlates with progression of differentiation, and CaMKK2 mRNA is present in myeloid progenitors but is undetectable in mature granulocytes (22). Taken together, the findings on adipogenesis, granulopoiesis, and CGCs (22, 23, 33) suggest an intriguing scenario in which CaMKK2 plays a more general role in progenitor cell biology, operating as a critical component of the signaling pathway that regulates proliferation, terminal differentiation, and commitment of progenitor cells toward a specific lineage.

Macrophages—Macrophages are phagocytes that play an essential role in clearing the body of debris, apoptotic cells, and pathogens (69). In lean subjects, macrophages display an attenuated inflammatory phenotype and protect adipose tissue from metabolic stress. Contrariwise, in response to overnutrition, monocytes recruited to adipose tissue develop into macrophages with a proinflammatory phenotype that play a causative role in the glucose intolerance and metabolic syndrome associated with obesity (70). Because macrophages release mediators that regulate all aspects of host defense, inflammation, and homeostasis, they play a critical role in the pathogenesis of sepsis and many other conditions characterized by an abnormal response to pathogens and stressing agents (71, 72).
Genetic ablation of CaMKK2 protects mice from diet-induced obesity, insulin resistance, and glucose intolerance (8). The ability of CaMKK2 to control food intake in the hypothalamus and gluconeogenesis in the liver contributes to this phenotype (8, 32). However, obesity is associated with a chronic inflammatory response that, in turn, causes abnormalities in glucose metabolism (73, 74). Thus, loss of CaMKK2 could also exert its effects, at least in part, by mitigating the inflammatory response to overnutrition, as this would attenuate the detrimental effects of chronic inflammation on glucose metabolism. Indeed, genetic ablation of CaMKK2 protects mice from diet-induced obesity, insulin resistance, and glucose intolerance (8).

Among blood cell types, CaMKK2 is expressed selectively in macrophages, and its ablation impairs the ability of macrophages to spread, phagocytize bacteria, and release cytokines/chemokines in response to LPS. This might seem incongruous because AMPKα, a known downstream effector of CaMKK2 in macrophages, negatively regulates macrophage activation and polarization and contributes to protection against obesity, inflammation, and insulin resistance (75–77). However, analysis of events proximal to the TLR4 signaling cascade indicates that, at early time points, LPS stimulation induces a decrease in phospho-AMPKα, and an increase in phospho-AMPK can be observed only at later time points (77). Thus, AMPKα activation may not be a direct consequence of TLR4 engagement but rather mediated by the wave of cytokines released by activated macrophages, such as IL-10 (77). Taken together, these data are not compatible with AMPKα being a downstream effector of CaMKK2 in TLR4-mediated signaling.

Actually, loss of macrophage CaMKK2 uncouples TLR4 signaling from the phosphorylation of PYK2/PTK2B (protein tyrosine kinase 2) and from activation of PYK2 downstream effectors, such as ERK1/2, NFκB, c-Jun, and AKT (35). CaMKK2 may regulate the stability and/or endosome recycling of PYK2, thus uncoupling the TLR4-dependent cascade. Thus, in macrophages as well as in neurons, CaMKK2 participates in signaling pathways controlling cytoskeleton remodeling and morphological changes induced by external stimuli (17, 27, 37).

**CaMKK2 and Prostate Cancer**

The androgen receptor (AR) regulates prostate growth and is the principal target of therapy aimed at preventing growth and spreading of androgen-dependent prostate cancer (78). In an
attempt to determine androgen‐responsive genes, two groups recently identified CaMKK2 to be associated with prostate cancer (79, 80). Frigo et al. (80) revealed that androgens stimulate the expression of CaMKK2 in androgen‐dependent prostate cancer cells. These authors also identified AMPKα as the downstream effector of CaMKK2 and identified CaMKK2 and AMPK as components of the signaling pathway downstream of the AR that mediates prostate cancer cell migration and invasion. Subsequently, Massie et al. (79) used a different strategy to identify CaMKK2 as a direct AR target, reporting that it is consistently overexpressed in prostate cancer based on analysis of nine independent clinical gene expression studies. This study consistently overexpressed in prostate cancer based on analysis of the expression of CaMKK2 in androgen‐dependent prostate cancer cells (79, 80). Frigo et al. (80) revealed that androgens stimulate the expression of CaMKK2 in androgen‐dependent prostate cancer cells. These authors also identified AMPKα as the downstream effector of CaMKK2 and identified CaMKK2 and AMPK as components of the signaling pathway downstream of the AR that mediates prostate cancer cell migration and invasion. Subsequently, Massie et al. (79) used a different strategy to identify CaMKK2 as a direct AR target, reporting that it is consistently overexpressed in prostate cancer based on analysis of nine independent clinical gene expression studies. This study also revealed that the AR directly up‐regulated expression of molecules required for glucose uptake and glycolysis. Pharmacological inhibition or siRNA‐mediated down‐regulation of CaMKK2 decreased phospho‐AMPKα, glycolytic flux, glucose uptake, and lactate and citrate production. Thus, the authors proposed CaMKK2 to be an important regulator of anabolic pathways downstream of the AR in prostate cancer cells (79).

**Concluding Remarks and Perspectives**

CaMKK2 is regulated at many levels by many signaling pathways (Fig. 2). Generation and/or splicing of the primary transcript is a regulated event, and in prostate cancer cells, transcription can be regulated by androgens (16, 17, 79, 80). CaMKK2 protein is also subject to numerous post‐translational modifications (Fig. 1) that affect protein stability and activity (27, 28). The cAMP/PKA pathway can inhibit CaMKK2 activity, and other inhibitory signals await discovery (81). As depicted in Fig. 2, CaMKK2 can be activated by signaling through Gq‐coupled receptors, inositol 1,4,5‐trisphosphate (IP3)‐mediated release of Ca2+ via activation of the IP3 receptor, Ca2+ entry into cells via plasma membrane ion channels, and Toll‐like receptors (5, 8, 34, 35). Intriguingly, CaMKK2 can also be activated by resveratrol, and because this field is still in its infancy, other stimulatory signals are likely to be discovered (82). Thus, it may be appropriate to consider CaMKK2 as a signaling hub that is capable of receiving and decoding signals transmitted via many diverse cellular regulatory pathways (Fig. 2). Considered in this light, CaMKK2 is one of the most versatile of the multifunctional CaMKs.

The information about CaMKK2 summarized herein suggests that it could be an attractive target for therapeutic intervention in liver and results in improved whole body glucose homeostasis, at least in part, by changing the primary hepatocyte fuel source from glucose to fat (32). In addition, depletion of CaMKK2 from preadipocytes accelerates their differentiation into adipocytes (33). Finally, among peripheral blood cells, CaMKK2 is expressed only in those of the myeloid lineage and controls the activation, cytokine production, phagocytosis, and motility of macrophages (35). Together, these actions conspire to render mice resistant to high‐fat diet‐induced glucose intolerance, insulin resistance, and diabetes. Mice deficient in CaMKK2 fail to accumulate fat when fed a high‐fat diet probably due in part to depletion of the preadipocyte pool during development and to the inability of macrophages to move into adipose tissue and produce the proinflammatory cytokines/chemokines that accelerate diabetes and progression to metabolic syndrome (33, 35). Because, at present, only one small‐molecule inhibitor of CaMKK2 has been reported (83), it might be prudent to renew the quest to identify potent, highly selective inhibitors of this versatile protein kinase.

**Acknowledgments**—We are profoundly grateful to our many research collaborators and scientific colleagues whose efforts made writing this minireview possible.

**REFERENCES**

1. Berridge, M. J. (2001) The versatility and complexity of calcium signaling. *Novartis Found. Symp.* 239, 52–64; discussion 64–57, 150–159
2. Chin, D., and Means, A. R. (2000) Calmodulin: a prototypical calcium sensor. *Trends Cell Biol.* 10, 322–328
3. Hook, S. S., and Means, A. R. (2001) Ca2+/CaM‐dependent kinases: from activation to function. *Annu. Rev. Pharmacol. Toxicol.* 41, 471–505
4. Soderling, T. R. (1999) The calcium/calmodulin‐dependent protein kinase cascade. *Trends Biochem. Sci.* 24, 232–236
5. Hawley, S. A., Pan, D. A., Mustard, K. I., Ross, L., Bain, J., Edelman, A. M., Frangioni, B. G., and Hardie, D. G. (2005) Calmodulin‐dependent protein kinase kinase β is an alternative upstream kinase for AMP‐activated protein kinase. *Cell Metab.* 2, 9–19
6. Woods, A., Dickerson, K., Heath, R., Hong, S. P., Momcilovic, M., Johnstone, S. R., Carlson, M., and Carling, D. (2005) Ca2+/calmodulin‐dependent protein kinase protein kinase β acts upstream of AMP‐activated protein kinase in mammalian cells. *Cell Metab.* 2, 21–33
7. Hurley, R. L., Anderson, K. A., Franzone, J. M., Kemp, B. E., Means, A. R., and Witters, L. A. (2005) The Ca2+/calmodulin‐dependent protein kinase kinases are AMP‐activated protein kinase kinases. *J. Biol. Chem.* 280, 29060–29066
8. Anderson, K. A., Ribar, T. J., Lin, F., Noeldner, P. K., Green, M. F., Muehlbauer, M. J., Witters, L. A., Kemp, B. E., and Means, A. R. (2008) Hypothalamic CaMKK2 contributes to the regulation of energy balance. *Cell Metab.* 7, 377–388
9. Tokumitsu, H., Brickey, D. A., Glod, J., Hidaka, H., Sikela, J., and Soderling, T. R. (1994) Activation mechanisms for Ca2+/calmodulin‐dependent protein kinase IV. Identification of a brain CaM kinase IV kinase. *J. Biol. Chem.* 269, 28640–28647
10. Kitani, T., Okuno, S., and Fujisawa, H. (1997) Molecular cloning of Ca2+/calmodulin‐dependent protein kinase β. *J. Biochem.* 122, 243–250
11. Tokumitsu, H., Enslen, H., and Soderling, T. R. (1995) Characterization of a Ca2+/calmodulin‐dependent protein kinase cascade. Molecular cloning and expression of calcium/calmodulin‐dependent protein kinase kinase. *J. Biol. Chem.* 270, 19320–19324
12. Anderson, K. A., Means, R. L., Huang, Q. H., Kemp, B. E., Goldstein, E. G., Selbert, M. A., Edelman, A. M., Fremeau, R. T., and Means, A. R. (1998) Components of a calmodulin‐dependent protein kinase cascade. Molecular cloning, functional characterization, and cellular localization of Ca2+/calmodulin‐dependent protein kinase β. *J. Biol. Chem.* 273, 31880–31889
13. Hsu, L. S., Tsou, A. P., Chi, C. W., Lee, C. H., and Chen, J. Y. (1998) Cloning, expression, and chromosomal localization of human Ca2+/calmodulin‐dependent protein kinase β. *J. Biol. Chem.* 273, 141–149
14. Vinet, J., Carra, S., Blom, J. M., Harvey, M., Brunello, N., Barden, N., and Tascos, F. (2003) Cloning of mouse Ca2+/calmodulin‐dependent protein kinase protein kinase β (CaMKKβ) and characterization of CaMKKβ and CaMKKα distribution in the adult mouse brain. *Brain Res. Mol. Brain Res.* 111, 216–221
15. Tokumitsu, H., Wayman, G. A., Muramatsu, M., and Soderling, T. R. (1997) Calcium/calmodulin‐dependent protein kinase: identification of regulatory domains. *Biochemistry* 36, 12823–12827
16. Hsu, L. S., Chen, G. D., Lee, L. S., Chi, C. W., Cheng, J. F., and Chen, J. Y. (2001) Human Ca2+/calmodulin‐dependent protein kinase protein kinase β gene encodes multiple isoforms that display distinct kinase activity. *J. Biol. Chem.* 276, 31113–31123
MINIREVIEW: CaMKK2 Signaling and Pathophysiology

59. He, L., Sabet, A., Djedjos, S., Miller, R., Sun, X., Hussain, M. A., Radovick, S., and Wondisford, F. E. (2009) Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Cell 137, 635–646.

60. Colomer, J., and Means, A. R. (2007) Physiological roles of the Ca\(^{2+}\)/CaM-dependent protein kinase cascade in health and disease. Subcell. Biochem. 45, 169–214.

61. Kitsos, C. M., Sankar, U., Illario, M., Colomer-Font, J. M., Duncan, A. W., Nakaya, H. I., Wrammert, J., Lee, E. K., Racioppi, L., Marie-Kunze, S., and Wondisford, F. E. (2009) Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Cell 137, 635–646.

62. Nakaya, H. I., Wrammert, J., Lee, E. K., Racioöppi, L., Marie-Kunze, S., Haining, W. N., Means, A. R., Kasturi, S. P., Khan, N., Li, G. M., McCausland, M., Kanchan, V., Kokko, K. E., Li, S., Elbein, R., Mehta, A. K., Aderem, A., Subbarao, K., Ahmed, R., and Pulendran, B. (2011) Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12, 786–795.

63. Illario, M., Giardino-Torchia, M. L., Sankar, U., Ribar, T. J., Galgani, M., Vitiello, L., Maschi, A. M., Bertani, F. R., Ciaglia, E., Astone, D., Mauclerc, G., Cavallo, A., Vitale, M., Cimini, V., Pastore, L., Means, A. R., Rossi, G., and Racioöppi, L. (2008) CaM-dependent kinase IV links Toll-like receptor 4 signaling with survival pathway of activated dendritic cells. Blood 111, 723–731.

64. Zhang, X., Guo, L., Collage, R. D., Stripay, J. L., Tsung, A., Lee, J. S., and Rosengart, M. R. (2011) Calcium/camodulin-dependent protein kinase (CaMK) \(\alpha\) mediates the macrophage inflammatory response to sepsis. J. Leukocyte. Biol. 90, 249–261.

65. Salminen, A., Hyttinen, J. M., and Kaarniranta, K. (2011) AMP-activated protein kinase inhibits NFkB signaling and inflammation: impact on health span and life span. J. Mol. Med. 89, 667–676.

66. Metcalf, D. (2007) Concise review: hematopoietic stem cells and tissue stem cells: current concepts and unanswered questions. Stem Cells 25, 2390–2395.

67. Adams, G. B., Chabner, K. T., Alley, I. R., Olson, D. P., Szczepiorkowski, Z. M., Poznansky, M. C., Kos, C. H., Pollak, M. R., Brown, E. M., and Scadden, D. T. (2006) Stem cell engrafment at the endothelial niche is specified by the calcium-sensing receptor. Nature 439, 599–603.

68. Lam, B. S., Cunningham, C., and Adams, G. B. (2011) Pharmacologic modulation of the calcium-sensing receptor enhances hematopoietic stem cell lodgment in the adult bone marrow. Blood 117, 1167–1175.

69. Laskin, D. L., Sunil, V. R., Gardner, C. R., and Laskin, J. D. (2011) Macrophages and tissue injury: agents of defense or destruction? Annu. Rev. Pharmacol. Toxicol. 51, 267–288.

70. Olefsky, J. M., and Glass, C. K. (2010) Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219–246.

71. Stearns-Kurosawa, D. J., Osuchowski, M. F., Valentine, C., Kurosawa, S., and Remick, D. G. (2011) The pathogenesis of sepsis. Annu. Rev. Pathol. 6, 19–48.

72. Gutierrez-Ramos, J. C., and Bluethmann, H. (1997) Molecules and mechanisms operating in septic shock: lessons from knock-out mice. Immunol. Today 18, 329–334.